This review highlights the central role of matrix metalloproteinases and their inhibitors in regulating the extracellular matrix during hypertension, contributing to left ventricular hypertrophy and reduced arterial compliance.
Does not yet support MMP-targeted therapy; extends mechanistic understanding of hypertensive remodeling.
The extracellular matrix (ECM) is a vital component of connective tissue, and collagen is a major constituent. There is growing evidence that changes in the composition of the cardiac and vascular matrix occurs during hypertension. Clinically, these effects are manifested as left ventricular hypertrophy and a reduction in arterial compliance and luminal diameter, which results in end organ ischaemia. The matrix metalloproteinases and their inhibitors have a central role in the regulation of the composition of the ECM. In this review, we discuss the mediators that affect the structure of the ECM in hypertension using results from animal and human studies.
No takes yet. Share an insight, caveat, or question.
Tayebjee et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: